Invitation
To the 1st symposium on minimal residual disease, Nordic countries
Minimal residual disease in hematological malignancies:
How deep is your response?
✓
Please see the full Agenda on page 2 for details.
Date and time: March 16th, 2017, 11.30-19.00
Venue: Park Inn by Radisson, Oslo Lufthavn, Henrik Ibsens veg, 2060 Gardermoen, Norway
LINK TO MAP
We are happy to extend an invitation to healthcare personnel with an interest in chronic lymphocytic leukemia and other
hematological malignancies to a seminar on minimal residual disease (MRD) at Gardermoen in Norway.
To register for this meeting, send an email to [email protected] or [email protected] with your name,
hospital and country. Please also specify whether you will be attending dinner or have any allergies. Deadline for signing up
is March 8th.
AbbVie and Roche cover meeting costs in accordance with regulations.
Participants must arrange and cover transportation and accommodation themselves.
Upon registration for this meeting, you confirm that you follow rules and regulations valid in your work place and have
obtained permission from your employer.
Best regards,
for AbbVie
for Roche
HILDE ABRAHAMSEN ENSERINK
Associated Head Medical Affairs
Hematology-Oncology
Nordic Countries
Mobile: +47 959 46 311
Email: [email protected]
SAEEDA RANA
Country Medical Manager
Mobile: +47 913 00 938
E-mail: [email protected]
agenda
11.30-12.30
REGISTRATION & LUNCH/COFFEE
12.30-12.45
Welcome and introduction
Session 1
12.45-13.30
Chair: Geir Tjønnfjord
MRD as a surrogate endpoint for PFS/OS in clinical trials
Dr. Sebastian Böttcher
Session 2
13.35-14.20
Chair: Carsten Niemann
MRD assessment in CLL and harmonization of method
Prof. Andy Rawstron
14.20-14.40 Break
Session 3
14.40-16.00
Chair: Geir Tjønnfjord
Current practices of MDR testing in different hematological malignancies
a) AML: Randi Hovland
b) MCL: Dr. Arne Kolstad
a) CLL: Dr. Carsten Niemann
b) FL: Prof. Eva Kimby
16.05-16.15 Break Session 4
16.15-17.00
Chair: Geir Tjønnfjord
Pros and cons of MRD in CLL: does it make sense to use MRD negativity as a therapeutic goal in hematological malignancies - are we there now?
by Prof. Peter Hillmen and Prof. Paolo Ghia
17.00-19.00 Dinner and networking
Welcome and general outlook on MRD in CLL
Prof. Geir Tjønnfjord and Dr. Carsten Niemann
NO/DAHE/1611/0004b. NOVEN170055. THAU
”Dette arrangementet arrangeres i samsvar med avtaler om samhandling som Legemiddelindustriforeningen har inngått med Den norske legeforening, Norges Farmaceutiske Forening, Norsk Sykepleierforbund og De regionale helseforetakene. For deg som helsepersonell medfører dette at både du og arrangøren har rettigheter og plikter
som skal sikre at arrangementet er av god faglig kvalitet og at det ikke er egnet til å skape forestillinger om uheldige bindinger mellom industri og helsepersonell. For mer
informasjon se www.lmi.no/standardinformasjon.